Comparative Pharmacology
Head-to-head clinical analysis: BARICITINIB versus VIVJOA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARICITINIB versus VIVJOA.
BARICITINIB vs VIVJOA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Baricitinib is a Janus kinase (JAK) inhibitor, selectively inhibiting JAK1 and JAK2, thereby modulating the signaling pathway involved in inflammatory responses.
VIVJOA (fosmanogepix) is a first-in-class antifungal agent that inhibits the fungal enzyme Gwt1, which is involved in glycosylphosphatidylinositol (GPI) anchor biosynthesis. This disrupts cell wall integrity and fungal growth.
2 mg orally once daily; may increase to 4 mg once daily if inadequate response.
VIVJOA (750 mg tablet) is administered as a single oral dose of 750 mg, taken once daily for 6 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 12.5 hours in healthy subjects; allowing once-daily dosing with steady-state reached in 2-3 days.
Clinical Note
moderateBaricitinib + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Baricitinib."
Clinical Note
moderateBaricitinib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Baricitinib."
Clinical Note
moderateBaricitinib + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Baricitinib."
Clinical Note
moderateBaricitinib + Cyclosporine
Terminal elimination half-life is approximately 20–26 hours, supporting once-daily dosing for sustained therapeutic levels.
Approximately 75% of the dose is excreted in urine (69% as unchanged drug, 6% as metabolites), and 20% in feces (15% unchanged, 5% metabolites).
Primarily hepatic metabolism via CYP3A4, with <1% excreted unchanged in urine; fecal elimination accounts for approximately 88% of the administered dose as metabolites.
Category C
Category C
JAK Inhibitor
JAK Inhibitor
"The metabolism of Cyclosporine can be decreased when combined with Baricitinib."